NeuroMetrix (NASDAQ:NURO) Now Covered by StockNews.com

Investment analysts at StockNews.com assumed coverage on shares of NeuroMetrix (NASDAQ:NURO) in a report issued on Monday. The brokerage set a “sell” rating on the medical device company’s stock.

NeuroMetrix Price Performance

NASDAQ NURO opened at $4.40 on Monday. NeuroMetrix has a fifty-two week low of $2.66 and a fifty-two week high of $4.73. The business has a fifty day moving average price of $4.41 and a two-hundred day moving average price of $4.19. The stock has a market capitalization of $9.07 million, a PE ratio of -0.96 and a beta of 1.82.

Hedge Funds Weigh In On NeuroMetrix

A hedge fund recently bought a new stake in NeuroMetrix stock. Renaissance Technologies LLC acquired a new position in shares of NeuroMetrix, Inc. (NASDAQ:NURO) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 11,560 shares of the medical device company’s stock, valued at approximately $46,000. Renaissance Technologies LLC owned approximately 0.57% of NeuroMetrix as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 19.40% of the company’s stock.

NeuroMetrix Company Profile

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.